Abstract
In response to selected stressors, cancer cells can undergo a form of regulated cell death that—in immunocompetent syngeneic hosts—is capable of eliciting an adaptive immune response specific for dead cell-associated antigens. Thus, such variant of regulated cell death manifests with robust antigenicity and adjuvanticity. As compared to their normal counterparts, malignant cells are highly antigenic per se, implying that they express a variety of antigens that are not covered by central tolerance. However, the precise modality through which cancer cells die in response to stress has a major influence on adjuvanticity. Moreover, the adjuvanticity threshold to productively drive anticancer immune responses is considerably lower in tumor-naïve hosts as compared to their tumor-bearing counterparts, largely reflecting the establishment of peripheral tolerance to malignant lesions in the latter (but not in the former). So far, no cellular biomarker or combination thereof has been found to reliably predict the ability of cancer cell death to initiate antitumor immunity. Thus, although some surrogate biomarkers of adjuvanticity can be used for screening purposes, the occurrence of bona fide immunogenic cell death (ICD) can only be ascertained in vivo. Here, we describe two methods that can be harnessed to straightforwardly determine the immunogenicity of mouse cancer cells succumbing to stress in both tumor-naïve and tumor-bearing hosts.
Takahiro Yamazaki and Aitziber Buqué contributed equally to this work.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Change history
08 November 2019
This book was inadvertently published with one of the contributing author’s name printed as Aitziber Buqué Martinez, which should have been Aitziber Buqué.
References
Fuchs Y, Steller H (2011) Programmed cell death in animal development and disease. Cell 147(4):742–758
Fuchs Y, Steller H (2015) Live to die another way: modes of programmed cell death and the signals emanating from dying cells. Nat Rev Mol Cell Biol 16(6):329–344
Ashkenazi A, Fairbrother WJ, Leverson JD, Souers AJ (2017) From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors. Nat Rev Drug Discov 16(4):273–284
Galluzzi L, Buque A, Kepp O, Zitvogel L, Kroemer G (2017) Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol 17(2):97–111
Kroemer G, Galluzzi L, Kepp O, Zitvogel L (2013) Immunogenic cell death in cancer therapy. Annu Rev Immunol 31:51–72
Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P, Vandenabeele P (2012) Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer 12(12):860–875
Galluzzi L, Baehrecke EH, Ballabio A, Boya P, Bravo-San Pedro JM, Cecconi F et al (2017) Molecular definitions of autophagy and related processes. EMBO J 36(13):1811–1836
Schumacher TN, Schreiber RD (2015) Neoantigens in cancer immunotherapy. Science 348(6230):69–74
Schumacher TN, Hacohen N (2016) Neoantigens encoded in the cancer genome. Curr Opin Immunol 41:98–103
Gubin MM, Artyomov MN, Mardis ER, Schreiber RD (2015) Tumor neoantigens: building a framework for personalized cancer immunotherapy. J Clin Invest 125(9):3413–3421
Yui MA, Rothenberg EV (2014) Developmental gene networks: a triathlon on the course to T cell identity. Nat Rev Immunol 14(8):529–545
Takaba H, Takayanagi H (2017) The mechanisms of T cell selection in the thymus. Trends Immunol 38(11):805–816
Brenner C, Galluzzi L, Kepp O, Kroemer G (2013) Decoding cell death signals in liver inflammation. J Hepatol 59(3):583–594
Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P et al (2018) Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018. Cell Death Differ 25(3):486–541
Galluzzi L, Kepp O, Chan FK, Kroemer G (2017) Necroptosis: mechanisms and relevance to disease. Annu Rev Pathol 12:103–130
Vitale I, Galluzzi L, Senovilla L, Criollo A, Jemaa M, Castedo M et al (2011) Illicit survival of cancer cells during polyploidization and depolyploidization. Cell Death Differ 18(9):1403–1413
Vitale I, Galluzzi L, Castedo M, Kroemer G (2011) Mitotic catastrophe: a mechanism for avoiding genomic instability. Nat Rev Mol Cell Biol 12(6):385–392
Stratton MR, Campbell PJ, Futreal PA (2009) The cancer genome. Nature 458(7239):719–724
Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW (2013) Cancer genome landscapes. Science 339(6127):1546–1558
Pon JR, Marra MA (2015) Driver and passenger mutations in cancer. Annu Rev Pathol 10:25–50
Garg AD, Martin S, Golab J, Agostinis P (2014) Danger signalling during cancer cell death: origins, plasticity and regulation. Cell Death Differ 21(1):26–38
Garg AD, Agostinis P (2017) Cell death and immunity in cancer: from danger signals to mimicry of pathogen defense responses. Immunol Rev 280(1):126–148
Garg AD, Galluzzi L, Apetoh L, Baert T, Birge RB, Bravo-San Pedro JM et al (2015) Molecular and translational classifications of DAMPs in immunogenic cell death. Front Immunol 6:588
Yatim N, Cullen S, Albert ML (2017) Dying cells actively regulate adaptive immune responses. Nat Rev Immunol 17(4):262–275
Linkermann A, Stockwell BR, Krautwald S, Anders HJ (2014) Regulated cell death and inflammation: an auto-amplification loop causes organ failure. Nat Rev Immunol 14(11):759–767
Chen GY, Nunez G (2010) Sterile inflammation: sensing and reacting to damage. Nat Rev Immunol 10(12):826–837
West AP, Shadel GS (2017) Mitochondrial DNA in innate immune responses and inflammatory pathology. Nat Rev Immunol 17(6):363–375
Broz P, Dixit VM (2016) Inflammasomes: mechanism of assembly, regulation and signalling. Nat Rev Immunol 16(7):407–420
Cao X (2016) Self-regulation and cross-regulation of pattern-recognition receptor signalling in health and disease. Nat Rev Immunol 16(1):35–50
Gay NJ, Symmons MF, Gangloff M, Bryant CE (2014) Assembly and localization of toll-like receptor signalling complexes. Nat Rev Immunol 14(8):546–558
Fridman WH, Zitvogel L, Sautes-Fridman C, Kroemer G (2017) The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol 14(12):717–734
Galluzzi L, Buque A, Kepp O, Zitvogel L, Kroemer G (2015) Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell 28(6):690–714
Vijayan D, Young A, Teng MWL, Smyth MJ (2017) Targeting immunosuppressive adenosine in cancer. Nat Rev Cancer 17(12):709–724
Kepp O, Senovilla L, Vitale I, Vacchelli E, Adjemian S, Agostinis P et al (2014) Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology 3(9):e955691
Dudek AM, Garg AD, Krysko DV, De Ruysscher D, Agostinis P (2013) Inducers of immunogenic cancer cell death. Cytokine Growth Factor Rev 24(4):319–333
Janicka M, Gubernator J (2017) Use of nanotechnology for improved pharmacokinetics and activity of immunogenic cell death inducers used in cancer chemotherapy. Expert Opin Drug Deliv 14(9):1059–1075
Sakaguchi S, Yamaguchi T, Nomura T, Ono M (2008) Regulatory T cells and immune tolerance. Cell 133(5):775–787
Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A (2017) Primary, adaptive, and acquired resistance to Cancer immunotherapy. Cell 168(4):707–723
Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH et al (2018) The immune landscape of cancer. Immunity 48(4):812–830.e814
Lu L, Barbi J, Pan F (2017) The regulation of immune tolerance by FOXP3. Nat Rev Immunol 17(11):703–717
Vanpouille-Box C, Alard A, Aryankalayil MJ, Sarfraz Y, Diamond JM, Schneider RJ et al (2017) DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Nat Commun 8:15618
Yamazaki T, Galluzzi L (2017) TREX1 cuts down on cancer immunogenicity. Trends Cell Biol 27(8):543–545
Demaria S, Ng B, Devitt ML, Babb JS, Kawashima N, Liebes L et al (2004) Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys 58(3):862–870
Ngwa W, Irabor OC, Schoenfeld JD, Hesser J, Demaria S, Formenti SC (2018) Using immunotherapy to boost the abscopal effect. Nat Rev Cancer 18(5):313–322
Rodriguez-Ruiz ME, Vanpouille-Box C, Melero I, Formenti SC, Demaria S (2018) Immunological mechanisms responsible for radiation-induced Abscopal effect. Trends Immunol 39(8):644–655
Golden EB, Chhabra A, Chachoua A, Adams S, Donach M, Fenton-Kerimian M et al (2015) Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial. Lancet Oncol 16(7):795–803
Golden EB, Demaria S, Schiff PB, Chachoua A, Formenti SC (2013) An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol Res 1(6):365–372
Weichselbaum RR, Liang H, Deng L, Fu YX (2017) Radiotherapy and immunotherapy: a beneficial liaison? Nat Rev Clin Oncol 14(6):365–379
Johnstone CD, Lindsay P, Graves EE, Wong E, Perez JR, Poirier Y et al (2017) Multi-institutional MicroCT image comparison of image-guided small animal irradiators. Phys Med Biol 62(14):5760–5776
Zhang Z, Wodzak M, Belzile O, Zhou H, Sishc B, Yan H et al (2016) Effective rat lung tumor model for stereotactic body radiation therapy. Radiat Res 185(6):616–622
Yamano T, Kubo S, Fukumoto M, Yano A, Mawatari-Furukawa Y, Okamura H et al (2016) Whole cell vaccination using immunogenic cell death by an oncolytic adenovirus is effective against a colorectal cancer model. Mol Ther Oncolytics 3:16031
Casares N, Pequignot MO, Tesniere A, Ghiringhelli F, Roux S, Chaput N et al (2005) Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 202(12):1691–1701
Sukkurwala AQ, Adjemian S, Senovilla L, Michaud M, Spaggiari S, Vacchelli E et al (2014) Screening of novel immunogenic cell death inducers within the NCI mechanistic diversity set. Oncoimmunology 3:e28473
Schrand B, Verma B, Levay A, Patel S, Castro I, Benaduce AP et al (2017) Radiation-induced enhancement of antitumor T-cell immunity by VEGF-targeted 4-1BB Costimulation. Cancer Res 77(6):1310–1321
Rodriguez-Ruiz ME, Rodriguez I, Garasa S, Barbes B, Solorzano JL, Perez-Gracia JL et al (2016) Abscopal effects of radiotherapy are enhanced by combined immunostimulatory mAbs and are dependent on CD8 T cells and crosspriming. Cancer Res 76(20):5994–6005
Lan Y, Zhang D, Xu C, Hance KW, Marelli B, Qi J et al (2018) Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-beta. Sci Transl Med 10(424):eaan5488
Rodriguez-Ruiz ME, Rodriguez I, Barbes B, Mayorga L, Sanchez-Paulete AR, Ponz-Sarvise M et al (2017) Brachytherapy attains abscopal effects when combined with immunostimulatory monoclonal antibodies. Brachytherapy 16(6):1246–1251
Lenk H, Muller U, Tanneberger S (1987) Mitoxantrone: mechanism of action, antitumor activity, pharmacokinetics, efficacy in the treatment of solid tumors and lymphomas, and toxicity. Anticancer Res 7(6):1257–1264
Vollmer T, Stewart T, Baxter N (2010) Mitoxantrone and cytotoxic drugs’ mechanisms of action. Neurology 74(Suppl 1):S41–S46
Fox EJ (2004) Mechanism of action of mitoxantrone. Neurology 63(12 Suppl 6):S15–S18
Parker C, Waters R, Leighton C, Hancock J, Sutton R, Moorman AV et al (2010) Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. Lancet 376(9757):2009–2017
Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME et al (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351(15):1513–1520
Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A et al (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362(14):1273–1281
Perilongo G, Maibach R, Shafford E, Brugieres L, Brock P, Morland B et al (2009) Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. N Engl J Med 361(17):1662–1670
Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V et al (2007) Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 357(17):1705–1715
Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C et al (2005) Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 352(25):2589–2597
Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J et al (2004) Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350(4):351–360
Galluzzi L, Vitale I, Michels J, Brenner C, Szabadkai G, Harel-Bellan A et al (2014) Systems biology of cisplatin resistance: past, present and future. Cell Death Dis 5:e1257
Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O et al (2012) Molecular mechanisms of cisplatin resistance. Oncogene 31(15):1869–1883
Siddik ZH (2003) Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22(47):7265–7279
Blazar BR, Taylor PA, Linsley PS, Vallera DA (1994) In vivo blockade of CD28/CTLA4: B7/BB1 interaction with CTLA4-Ig reduces lethal murine graft-versus-host disease across the major histocompatibility complex barrier in mice. Blood 83(12):3815–3825
Torsvik A, Stieber D, Enger PO, Golebiewska A, Molven A, Svendsen A et al (2014) U-251 revisited: genetic drift and phenotypic consequences of long-term cultures of glioblastoma cells. Cancer Med 3(4):812–824
Capes-Davis A, Reid YA, Kline MC, Storts DR, Strauss E, Dirks WG et al (2013) Match criteria for human cell line authentication: where do we draw the line? Int J Cancer 132(11):2510–2519
Terenzi A, Pirker C, Keppler BK, Berger W (2016) Anticancer metal drugs and immunogenic cell death. J Inorg Biochem 165:71–79
Galluzzi L, Morselli E, Vitale I, Kepp O, Senovilla L, Criollo A et al (2010) miR-181a and miR-630 regulate cisplatin-induced cancer cell death. Cancer Res 70(5):1793–1803
Martins I, Kepp O, Schlemmer F, Adjemian S, Tailler M, Shen S et al (2011) Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress. Oncogene 30(10):1147–1158
Tesniere A, Schlemmer F, Boige V, Kepp O, Martins I, Ghiringhelli F et al (2010) Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 29(4):482–491
Garg AD, More S, Rufo N, Mece O, Sassano ML, Agostinis P et al (2017) Trial watch: immunogenic cell death induction by anticancer chemotherapeutics. Oncoimmunology 6(12):e1386829
Bezu L, Gomes-de-Silva LC, Dewitte H, Breckpot K, Fucikova J, Spisek R et al (2015) Combinatorial strategies for the induction of immunogenic cell death. Front Immunol 6:187
Michaud M, Martins I, Sukkurwala AQ, Adjemian S, Ma Y, Pellegatti P et al (2011) Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 334(6062):1573–1577
Bezu L, Sauvat A, Humeau J, Gomes-da-Silva LC, Iribarren K, Forveille S et al (2018) eIF2alpha phosphorylation is pathognomonic for immunogenic cell death. Cell Death Differ 25(8):1375–1393
Vacchelli E, Ma Y, Baracco EE, Sistigu A, Enot DP, Pietrocola F et al (2015) Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1. Science 350(6263):972–978
Sistigu A, Yamazaki T, Vacchelli E, Chaba K, Enot DP, Adam J et al (2014) Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med 20(11):1301–1309
Golden EB, Frances D, Pellicciotta I, Demaria S, Helen Barcellos-Hoff M, Formenti SC (2014) Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death. Oncoimmunology 3:e28518
Vacchelli E, Bloy N, Aranda F, Buque A, Cremer I, Demaria S et al (2016) Trial watch: immunotherapy plus radiation therapy for oncological indications. Oncoimmunology 5(9):e1214790
Wu J, Waxman DJ (2018) Immunogenic chemotherapy: dose and schedule dependence and combination with immunotherapy. Cancer Lett 419:210–221
Wu J, Waxman DJ (2015) Metronomic cyclophosphamide eradicates large implanted GL261 gliomas by activating antitumor Cd8(+) T-cell responses and immune memory. Oncoimmunology 4(4):e1005521
Jiang L, Paone S, Caruso S, Atkin-Smith GK, Phan TK, Hulett MD et al (2017) Determining the contents and cell origins of apoptotic bodies by flow cytometry. Sci Rep 7(1):14444
Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL et al (2007) Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13(1):54–61
Naik S, Bouladoux N, Linehan JL, Han SJ, Harrison OJ, Wilhelm C et al (2015) Commensal-dendritic-cell interaction specifies a unique protective skin immune signature. Nature 520(7545):104–108
Ginhoux F, Ng LG, Merad M (2012) Understanding the murine cutaneous dendritic cell network to improve intradermal vaccination strategies. Curr Top Microbiol Immunol 351:1–24
Karreman MA, Ruthensteiner B, Mercier L, Schieber NL, Solecki G, Winkler F et al (2017) Find your way with X-ray: using microCT to correlate in vivo imaging with 3D electron microscopy. Methods Cell Biol 140:277–301
Winkelmann CT, Figueroa SD, Sieckman GL, Rold TL, Hoffman TJ (2012) Non-invasive microCT imaging characterization and in vivo targeting of BB2 receptor expression of a PC-3 bone metastasis model. Mol Imaging Biol 14(6):667–675
Galluzzi L, Vanpouille-Box C, Bakhoum SF, Demaria S (2018) SnapShot: CGAS-STING Signaling. Cell 173(1):276–276.e1
Vanpouille-Box C, Formenti SC, Demaria S (2017) TREX1 dictates the immune fate of irradiated cancer cells. Oncoimmunology 6(9):e1339857
Hoos A (2016) Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations. Nat Rev Drug Discov 15(4):235–247
Ribas A, Wolchok JD (2018) Cancer immunotherapy using checkpoint blockade. Science 359(6382):1350–1355
Vanpouille-Box C, Diamond JM, Pilones KA, Zavadil J, Babb JS, Formenti SC et al (2015) TGFbeta is a master regulator of radiation therapy-induced antitumor immunity. Cancer Res 75(11):2232–2242
Sharpe AH, Pauken KE (2018) The diverse functions of the PD1 inhibitory pathway. Nat Rev Immunol 18(3):153–167
Vanpouille-Box C, Demaria S, Formenti SC, Galluzzi L (2018) Cytosolic DNA sensing in organismal tumor control. Cancer Cell 34(3):361–378
Acknowledgments
The authors are supported by a Breakthrough Level 2 grant from the US Department of Defense (DoD), Breast Cancer Research Program (BRCP) (#BC180476P1), by a startup grant from the Dept. of Radiation Oncology at Weill Cornell Medicine (New York, USA), by industrial collaborations with Lytix (Oslo, Norway) and Phosplatin (New York, USA), and by donations from Phosplatin (New York, USA), the Luke Heller TECPR2 Foundation (Boston, USA), and Sotio a.s. (Prague, Czech Republic).
Author Disclosure: L.G. provides remunerated consulting to OmniSEQ (Buffalo, NY, USA), Astra Zeneca (Gaithersburg, MD, USA), VL47 (New York, NY, USA), and the Luke Heller TECPR2 Foundation (Boston, MA, USA), and he is member of the Scientific Advisory Committee of OmniSEQ (Buffalo, NY, USA). The other authors have no conflicts of interest to disclose.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Yamazaki, T., Buqué, A., Rybstein, M., Chen, J., Sato, A., Galluzzi, L. (2020). Methods to Detect Immunogenic Cell Death In Vivo. In: Thurin, M., Cesano, A., Marincola, F. (eds) Biomarkers for Immunotherapy of Cancer. Methods in Molecular Biology, vol 2055. Humana, New York, NY. https://doi.org/10.1007/978-1-4939-9773-2_20
Download citation
DOI: https://doi.org/10.1007/978-1-4939-9773-2_20
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-4939-9772-5
Online ISBN: 978-1-4939-9773-2
eBook Packages: Springer Protocols